Generex Biotechnology to Make Presentations at the 2nd International Congress on “Prediabetes” and the Metabolic Syndrome

Generex Biotechnology Corporation (NASDAQ: GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it will be making three poster presentations at the 2nd International Congress on “Prediabetes” and the Metabolic Syndrome: Epidemiology, Management and Prevention of Diabetes and Cardiovascular Disease (www.kenes.com/prediabetes) in Barcelona, Spain, April 25 – 28, 2007.

The Company will be making the following poster presentations:

 —  Metformin Gum: An Alternative Method for Delivery of Biguanides      —  Pre-Prandial S.C. Regular Insulin Versus Prandial Generex Oral-lyn(TM)     in Type-1 DM Subjects Maintained in Basal S.C. Twice Daily Isophane Insulin     (NPH)      —  Oral Insulin at Lunchtime in Juvenile Type-1 DM Subjects Maintained on     Basal Glargine Insulin and Pre-Breakfast and Pre-Dinner Regular Insulin      

These posters were co-authored by Doctors Jaime Guevara-Aguirre, Marco Guevara-Aguirre, and Jeannette Saavedra, all of the Institute of Endocrinology IEMYR, Quito, Ecuador. In addition, Dr. David Saldarreaga of IEMYR contributed to the metformin gum study and Dr. Gerald Bernstein, the Generex Vice-President for Medical Affairs, contributed to the study of juvenile patients.

Prediabetes and the Metabolic Syndrome are highly prevalent conditions, affecting between one in six and one in three adults in most developed countries, as well as the urban areas of many developing countries. Both conditions are of significant public health importance because they are associated with a markedly increased risk of diabetes and cardiovascular disease (CVD), thus contributing to the epidemic proportions of these diseases. Diabetes is an important CVD risk factor. Impaired glucose metabolism among cardiac patients is extremely prevalent, and research on the impact of dysglycemia on patients with CVD is expanding. The 2nd International Congress on “Prediabetes” and the Metabolic Syndrome will provide a platform for both doctors and pharmaceutical companies to present their studies and the many new developments in prevention of diabetes and CVD.

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company’s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company’s proprietary RapidMist(TM) device. The Company’s flagship product, oral insulin (Generex Oral-lyn(TM)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. For more information, visit the Generex website at www.generex.com.

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as “expects,”"plans,”"intends,”"believes,”"will,”"estimates,”"forecasts,”"projects” or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any “phase” of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

 For more information, please contact:  For Generex: Shayne Gilliatt of Generex 800-391-6755 or 416-364-2551  Andrew Hellman of CEOcast, Inc. 212-732-4300  

SOURCE: Generex Biotechnology